Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company usually posts poor financials for mid or long term investments.
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • The share is getting closer to its long-term support in weekly data, at EUR 42.43, which offers good timing for buyers.
  • Share prices are approaching a strong support area in daily data, which offers good timing for investors.
  • The company is one of the best yield companies with high dividend expectations.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The company is in debt and has limited leeway for investment
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The group usually releases earnings worse than estimated.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The technical configuration over the long term remains negative on the weekly chart below the resistance level at 57.22 EUR
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
BAYER AG-41.55%49 406
JOHNSON & JOHNSON-1.30%379 007
ROCHE HOLDING AG-4.55%282 543
PFIZER INC.-3.22%210 717
MERCK & CO., INC.-13.32%199 405
NOVARTIS AG-16.94%185 381
NOVO NORDISK A/S13.53%162 074
ABBVIE INC.-5.22%148 105
ASTRAZENECA PLC6.18%137 968
BRISTOL-MYERS SQUIBB COMPAN..-7.04%134 492
AMGEN INC.-6.71%131 717
ELI LILLY AND COMPANY7.81%128 447
SANOFI-7.59%122 965
GLAXOSMITHKLINE PLC-24.41%87 133
JIANGSU HENGRUI MEDICINE CO..22.34%70 209
CHUGAI PHARMACEUTICAL CO., ..24.38%65 317
More Results
Financials
Sales 2020 42 947 M 50 623 M 50 623 M
Net income 2020 -4 611 M -5 435 M -5 435 M
Net Debt 2020 32 544 M 38 361 M 38 361 M
P/E ratio 2020 -6,81x
Yield 2020 5,76%
Capitalization 41 173 M 48 726 M 48 532 M
EV / Sales 2020 1,72x
EV / Sales 2021 1,68x
Nbr of Employees 101 168
Free-Float 100,0%
Upcoming event on BAYER AG
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes